pharma · Ischemic Stroke
Hui-Sheng Chen
Hui-Sheng Chen is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ischemic Stroke. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity f
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 3
- Patents
- 0
Intra-arterial administration of neuroprotective agents
Unknown · small molecule · Ischemic Stroke
Intra-arterial administration of neuroprotective agents for Ischemic Stroke is a Unknown program (small_molecule) at Hui-Sheng Chen with 1 ClinicalTrials.gov record(s).
Internal code k（2020）31
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hui-Sheng Chen
- Phase
- Unknown
- Modality
- small_molecule
- Indication
- Ischemic Stroke
- Status
- active
- Trials
- 1